Quest Diagnostics Incorporated (DGX)

Rating: HOLD

HOLD (5-tier) · mature cash generator · conviction: low

EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).

Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.

General research for a skeptical institutional reader. Not personalised investment advice; no position sizing or trade instructions. Figures as of the analysis date; verify before acting.

Investment Committee Summary

📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -4% vs spot
• Monte Carlo median implies -12% vs spot
• DCF fair value implies -48% vs spot
• Bear case (Structural — Reimbursement / In-House Testing) downside is -58% vs spot
• Net: reward/risk of 0.5× is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Investment Thesis

At $211.95 (27 June 2026), Quest trades within a dollar of its 52-week high of $212.58 and on 19.7x forward earnings against a lab-peer median of 14.5x. The market is paying a quality premium for a roughly 3 pct organic grower, implying confidence that advanced-diagnostics mix and bolt-on M&A compound earnings without reimbursement interruption. The engine is less generous. The probability-weighted target of $204 sits about 4 pct below spot, the Monte Carlo puts the chance of upside at 41 pct, and both DCF anchors ($114 to $123 per share) sit far below the market price: the equity is carried by its multiple, not by discounted cash flow. Margin is the dominant variance driver at 57 pct of simulated dispersion, on a business earning roughly 14 pct operating margins with limited room for error. HOLD follows: probability-weighted value approximates the current price, with a fatter left tail than right. The single most damaging risk is a Medicare fee-schedule cut arriving alongside payer-driven in-house testing, compressing earnings and the multiple together.

The dashboard below is the whole argument on one page: spot ($212) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The structural bear case does not require a recession; it requires payers to act in their own interest. Medicare fee-schedule cuts have precedent under PAMA, and commercial insurers are steering volume toward narrow lab networks just as large health systems rebuild in-house testing to capture the margin themselves. Quest's 14 pct operating margin is the arbitrage being competed away. In that world organic volumes stagnate, revenue per requisition falls, and the 19.7x forward multiple, priced for a quality compounder, de-rates toward 11x for a structurally pressured processor. The scenario maths land near $90, below the 52-week low of $162, on a 20 pct probability. Debt-funded M&A, with $6.6 billion of net debt already outstanding, would accelerate rather than cushion the fall.

Key Debate

Gross Margin explains 57% of Monte Carlo outcome variance — the single variable that decides which side is right.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q1): management +0.56 vs analyst floor +0.38 → delta +0.18 (n=25 mgmt / 13 Q&A; 11th pctile across the S&P book, z -1.3).

Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).

News (last 365d, 985 articles): avg ticker sentiment +0.21 (bullish 28% / bearish 2%)

Scenario Analysis

The tree runs from a structural 'Structural — Reimbursement / In-House Testing' downside ($89) to a 'Bull — Re-Rate' bull case ($361); the probability-weighted blend (PWEV $204) is -4% versus spot.

Scenario rationale — what each probability buys (the driver path behind every target):

• Structural — Reimbursement / In-House Testing (20%, $89). Structural impairment — reimbursement / in-house testing: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 89.87; probability: 0.2.
• Volume Recession (17%, $153). Cyclical downturn — diagnostic test volumes + reimbursement rates + advanced-test mix + M&A weakens for 1–2 years before normalising. Drivers — implied_target: 152.62; probability: 0.17.
• Base — Volume + Acquisitions (35%, $212). Mid-cycle — normalised diagnostic test volumes + reimbursement rates + advanced-test mix + M&A; disciplined capital allocation; steady returns. Drivers — implied_target: 211.97; probability: 0.35.
• Growth — Advanced-Diagnostics / M&A (20%, $287). Upside — advanced diagnostics + M&A lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 286.15; probability: 0.2.
• Bull — Re-Rate (8%, $361). Upside tail — sustained tight conditions or a structural re-rate on advanced diagnostics + M&A. Drivers — implied_target: 361.4; probability: 0.08.

Valuation Triangulation

Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Rating vs blend — the key debate. The rating tracks the multiple-discipline fair value (Monte Carlo $187 + scenario PWEV $204, ≈ spot); the weighted blend $157 (-26%) sits below it because the cash-flow DCF ($111) is materially more conservative than the market multiple. Whether the current multiple is justified is the central question for this name — and the principal downside risk to the rating.

Monte Carlo — the distribution, not a point

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $187 and 40% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (57% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 16x terminal FCF multiple → $111. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median forward multiple (P/E 14.455x) implies $155. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.

Across all anchors the spread is 92% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Services

This name sits in the Health Services as a diagnostics. diagnostic test volumes + reimbursement rates + advanced-test mix + M&A Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: MCK (distributors) · COR (distributors) · CAH (distributors) · DGX (diagnostics) · LH (diagnostics) · HSIC (distributors)

Mapping note: name-level 'Structural — Reimbursement / In-House Testing' (20%) + 'Volume Recession' (17%) map to cluster Reimbursement / Disintermediation Pressure (37%); name-level 'Growth — Advanced-Diagnostics / M&A' (20%) + 'Bull — Re-Rate' (8%) map to cluster Upside — Specialty / M&A Re-Rate (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Reimbursement / Disintermediation Pressure () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The health_services cycle is the shared macro driver. Driver — drug/lab volumes + reimbursement + thin-margin distribution & specialty mix Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $5B + PV(terminal) $14B = EV $19B; + net cash → equity $12B ÷ diluted shares 0.11B = $111/share (exit-multiple terminal).

• Gordon (perpetuity-growth) terminal at 2.5% → $119/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 6% vs WACC 8% → below WACC — the incremental build is value-dilutive.

Peer set

Peer-median fwd P/E → $155; EV/Rev → $62.

Weighted fair-value math

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Diagnostics & Lab Services multiple (AI re-rating) (base 19x)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 0.8% of revenue; cash conversion (OCF/NI) 180% — cash-backed.

Catalyst Calendar

• 2026-07-23 (~15d) — Quarterly earnings — est. EPS $2.81 (AV EARNINGS_CALENDAR)
• 2026-09-01 (~55d) — Bolt-on lab-acquisition / hospital outreach-purchase milestone (authored)
• 2026-11-15 (~130d) — PAMA / CMS Clinical Lab Fee Schedule reimbursement-rate decision for the coming year (authored)
• 2027-01-30 (~206d) — FY2026 results and FY2027 organic-growth / M&A-contribution guidance (authored)

Forecast Track Record

• EPS surprise: beat 100.0% of the last 8 quarters; average surprise +2.7%.

Competitive Moat

Narrow moat. Quest's moat is scale and network density in routine lab testing - the largest US independent lab logistics footprint, health-plan in-network contracts, and physician/EHR connectivity - plus a growing advanced-diagnostics menu. This is a narrow cost-scale moat exposed to reimbursement (PAMA/CMS) pressure and hospital in-sourcing. A narrow moat with reimbursement risk should trade near, not far above, the lab-peer median; the falsifiable claim is that the ~20x forward premium to the 14.5x peer median is unjustified unless advanced-diagnostics mix and M&A demonstrably lift organic growth above ~3-4% - otherwise the terminal multiple should compress toward peers.

Moat sources:

• Scale and logistics density: national specimen-transport and lab network hard to replicate
• Health-plan in-network contracts and preferred-lab agreements (e.g., UnitedHealthcare) driving volume
• Physician-office and EHR connectivity creating ordering-workflow stickiness
• Reimbursement (PAMA/CMS) and hospital in-sourcing structurally cap pricing power (moat limiter)

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

What the Market Is Pricing In

At the current price, the market pays 18.2× forward EPS, vs the house DCF terminal 16.0×, and a peer median 14.455×. The house DCF sits 48% below spot, so the market is pricing in more than the house case — roughly 3.5pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily event-driven.

Peer Quality & Weighting

Quality-weighted forward P/E: 13.2× (simple median 14.455×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $162–$213, centre $186 (-12% vs spot); spot sits at the 100th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

Reward/risk compares triangulated upside against the probability-weighted bear target, not the extreme tail. Bull case (Bull — Re-Rate): $361.

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (75.0); Revenue CAGR ±3pp (46.0); Terminal × ±15% (38.0); Capex intensity ±15% (25.0); WACC ±1pp (14.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Source Log

Citation coverage: 13/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.

Load-Bearing Assumptions

DCF: WACC 8%, terminal multiple 16×, FY+5 revenue $13B. Triangulation leans 41% on DCF, 29% on PWEV.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic revenue growth (ex-M&A), year on year < 0.01 (2 consecutive prints → health_services: Reimbursement / Disintermediation Pressure). Base case assumes roughly 3.0 pct organic growth from volumes and advanced-test mix. Two prints below 1.0 pct means volume or steerage pressure is real, shifting weight toward the Volume Recession path.
• Adjusted operating margin < 0.133 (2 consecutive prints → health_services: Reimbursement / Disintermediation Pressure). Margin drives 57 pct of simulated valuation variance. Two prints below 13.3 pct signal reimbursement or wage/supply cost pressure that the Invigorate-style cost programmes are not offsetting.
• Enacted Medicare Clinical Lab Fee Schedule change (annual rate) < -2.0 pct (single event → health_services: Reimbursement / Disintermediation Pressure). A PAMA-style fee-schedule cut of 2.0 pct or worse flows almost entirely to operating profit and validates the structural scenario mechanism of earnings and multiple compressing together.
• Revenue per requisition, year on year < -0.015 (2 consecutive prints → health_services: Reimbursement / Disintermediation Pressure). Falling unit revenue while volumes hold indicates payer steerage to narrow networks or hospital in-sourcing capturing the mix, the core disintermediation mechanism in the bear path.
• Net debt / EBITDA after announced M&A > 3.25 (single event → health_services: Mid-Cycle — Volume + Specialty Growth). Net debt is already $6.6B (~2.8x EBITDA). A deal that pushes leverage past 3.25x removes the balance-sheet cushion that makes bolt-on M&A a credible growth pillar rather than a risk amplifier.

Fact / Inference / Speculation

• FACT: Spot $212; 52-week range $162–$213; engine rating HOLD; base-case target $204 (-4%). (source: Alpha Vantage 2026-06-27, 8 July 2026)
• INFERENCE: Triangulated FV $157 (-26% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that Gross Margin keeps surprising favourably — an operating call the next two prints will test.

Recommendation: HOLD

Balanced: triangulated fair value $157 (-26% vs spot); the outcome hinges on Gross Margin. The debate is Gross Margin — a fundamental call.

Disclosures & Limitations

This report is for informational and research purposes only. It is not personalised investment advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.

• No suitability assessment has been performed for any individual.
• Market data may be delayed or inaccurate; figures are as of the analysis date.
• Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
• Forecasts are uncertain; past performance is not indicative of future returns.
• The author or publisher may hold positions in securities mentioned.
• Users should verify information against primary sources (company filings) before acting.
• Investing involves risk of loss; there is no guarantee any target price is achieved.
• Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.